195 related articles for article (PubMed ID: 15139567)
1. Improved delivery of ipratropium bromide/fenoterol from Respimat Soft Mist Inhaler in patients with COPD.
Kilfeather SA; Ponitz HH; Beck E; Schmidt P; Lee A; Bowen I; Hesse Ch
Respir Med; 2004 May; 98(5):387-97. PubMed ID: 15139567
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat Soft Mist Inhaler vs. a conventional metered dose inhaler plus spacer in children with asthma.
von Berg A; Jeena PM; Soemantri PA; Vertruyen A; Schmidt P; Gerken F; Razzouk H
Pediatr Pulmonol; 2004 Mar; 37(3):264-72. PubMed ID: 14966821
[TBL] [Abstract][Full Text] [Related]
3. A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease.
Kässner F; Hodder R; Bateman ED
Drugs; 2004; 64(15):1671-82. PubMed ID: 15257628
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Efficacy and Safety of Ipratropium Bromide plus Fenoterol via Respimat((R)) Soft Misttrade mark Inhaler (SMI) versus a Pressurised Metered-Dose Inhaler in Asthma.
Vincken W; Bantje T; Middle MV; Gerken F; Moonen D
Clin Drug Investig; 2004; 24(1):17-28. PubMed ID: 17516687
[TBL] [Abstract][Full Text] [Related]
5. Improved delivery of fenoterol plus ipratropium bromide using Respimat compared with a conventional metered dose inhaler.
Goldberg J; Freund E; Beckers B; Hinzmann R
Eur Respir J; 2001 Feb; 17(2):225-32. PubMed ID: 11334124
[TBL] [Abstract][Full Text] [Related]
6. Respimat (a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients.
Kunkel G; Magnussen H; Bergmann K; Juergens UR; de Mey C; Freund E; Hinzmann R; Beckers B
Respiration; 2000; 67(3):306-14. PubMed ID: 10867600
[TBL] [Abstract][Full Text] [Related]
7. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique.
Brand P; Hederer B; Austen G; Dewberry H; Meyer T
Int J Chron Obstruct Pulmon Dis; 2008; 3(4):763-70. PubMed ID: 19281091
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI.
Zuwallack R; De Salvo MC; Kaelin T; Bateman ED; Park CS; Abrahams R; Fakih F; Sachs P; Pudi K; Zhao Y; Wood CC;
Respir Med; 2010 Aug; 104(8):1179-88. PubMed ID: 20172704
[TBL] [Abstract][Full Text] [Related]
9. Delivery of fenoterol via Respimat, a novel 'soft mist' inhaler. a randomised, double-blind (within device), placebo-controlled, cross-over, dose-ranging study in asthmatic patients.
van Noord JA; Smeets JJ; Creemers JP; Greefhorst LP; Dewberry H; Cornelissen PJ
Respiration; 2000; 67(6):672-8. PubMed ID: 11124651
[TBL] [Abstract][Full Text] [Related]
10. Improved delivery of ipratropium bromide using Respimat (a new soft mist inhaler) compared with a conventional metered dose inhaler: cumulative dose response study in patients with COPD.
Iacono P; Velicitat P; Guemas E; Leclerc V; Thébault JJ
Respir Med; 2000 May; 94(5):490-5. PubMed ID: 10868713
[TBL] [Abstract][Full Text] [Related]
11. Preliminary data from phase II studies with Respimat, a propellant-free soft mist inhaler.
Pavia D; Moonen D
J Aerosol Med; 1999; 12 Suppl 1():S33-9. PubMed ID: 10623340
[TBL] [Abstract][Full Text] [Related]
12. Fenoterol delivery by Respimat soft mist inhaler versus CFC metered dose inhaler: cumulative dose-response study in asthma patients.
Vincken W; Dewberry H; Moonen D
J Asthma; 2003 Sep; 40(6):721-30. PubMed ID: 14580004
[TBL] [Abstract][Full Text] [Related]
13. Respimat Soft Mist inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfaction.
Schürmann W; Schmidtmann S; Moroni P; Massey D; Qidan M
Treat Respir Med; 2005; 4(1):53-61. PubMed ID: 15725050
[TBL] [Abstract][Full Text] [Related]
14. Low incidence of paradoxical bronchoconstriction in asthma and COPD patients during chronic use of Respimat soft mist inhaler.
Hodder R; Pavia D; Dewberry H; Alexander K; Iacono P; Ponitz H; Beck E
Respir Med; 2005 Sep; 99(9):1087-95. PubMed ID: 15893465
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the safety of drug delivery via HFA- and CFC-metered dose inhalers in CAO.
Huchon G; Hofbauer P; Cannizzaro G; Iacono P; Wald F
Eur Respir J; 2000 Apr; 15(4):663-9. PubMed ID: 10780756
[TBL] [Abstract][Full Text] [Related]
17. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.
Voshaar T; Lapidus R; Maleki-Yazdi R; Timmer W; Rubin E; Lowe L; Bateman E
Respir Med; 2008 Jan; 102(1):32-41. PubMed ID: 17996436
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic equivalence of a novel HFA134a-containing metered-dose inhaler and the conventional CFC inhaler (Berodual) for the delivery of a fixed combination of fenoterol/ipratropium bromide. A randomized double-blind placebo-controlled crossover study in patients with asthma.
Maesen FP; Greefhorst LP; Smeets JJ; Wald FD; Cornelissen PJ
Respiration; 1997; 64(4):273-80. PubMed ID: 9257362
[TBL] [Abstract][Full Text] [Related]
19. Fenoterol hydrobromide delivered via HFA-MDI or CFC-MDI in patients with asthma: a safety and efficacy comparison.
Goldberg J; Böhning W; Schmidt P; Freund E
Respir Med; 2000 Oct; 94(10):948-53. PubMed ID: 11059947
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic equivalence of a fenoterol/ipratropium bromide combination (Berodual) inhaled as a dry powder and by metered dose inhaler in chronic obstructive airway disease.
Rammeloo RH; Luursema PB; Sips AP; Beumer HM; Wald FD; Cornelissen PJ
Respiration; 1992; 59(6):322-6. PubMed ID: 1488568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]